Del Mar Pharma Announces Strategic Collaboration In China

Del Mar Pharma announced on Monday a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083, known in China as DAG for Injection.

AsianScientist (Oct. 30, 2012) – Del Mar Pharmaceuticals (BC) Ltd. announced on Monday a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company, a subsidiary of the publicly traded Guangxi Wuzhou Zhongheng Group Co., Ltd, for the development of VAL-083, known in China as DAG for Injection.

DAG for Injection has been approved by the Chinese State Food and Drug Administration (SFDA) for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Guangxi Wuzhou Pharmaceuticals is licensed by the SFDA to manufacture and sell VAL-083 in China for these indications.

DelMar is conducting clinical studies on VAL-083 in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

In addition, DelMar is conducting research aimed at demonstrating the utility of DAG for Injection in cancers refractory to current therapies. Recently published data showed sub-types of CML and lung cancer that are uniquely found in persons of East Asian decent and highly resistant to treatment by tyrosine kinase inhibitors (TKIs). DelMar’s research demonstrates activity against cancer cell lines resistant to TKI therapy.

The Companies plan to use new data being generated through DelMar’s clinical programs to expand the market for VAL-083 within and outside of China.

Other goals are to ensure that the product specifications meet global standards to accelerate international development and regulatory approval. Wuzhou Pharmaceuticals will be the exclusive supplier of DAG for Injection and DelMar will be responsible for development and commercialization.

The expanded collaboration was announced at a joint press conference and signing ceremony in Wuzhou, China on October 24, 2012.

“It is understood that, through this collaboration, we will seek to establish approval of DAG for Injection through international authorities including FDA and EMEA and other international jurisdictions outside China for multiple indications including brain cancer,” said Xu Shuqin, Chairman of the Zhongheng Group.

——

Source: Del Mar Pharmaceuticals (BC) Ltd.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist